Gilead Science Inc’s antiviral drug remdesivir was granted emergency use authorisation by the US Food and Drug Administration for COVID-19, clearing the way for broader use of the drug in more hospitals around the United States.

During a meeting in the Oval Office of the White House with President Donald Trump, Gilead Chief Executive Daniel O’Day called the move an important first step and said the company was donating 1.5 million vials of the drug to help patients.

The donation is expected to be enough for at least 140,000 patients, depending on the number of days they need to be treated.

Read full story here.

Opinion

Editorial

Climate choices
Updated 15 Jun, 2026

Climate choices

The country is confronting increasingly volatile weather patterns with consequences for agriculture, infrastructure, public health and economic planning.
Brief opening
15 Jun, 2026

Brief opening

WE have been here before. Throughout the weekend, there was great anticipation that a tentative framework for peace...
Environmental disaster
15 Jun, 2026

Environmental disaster

IT was a heartbreaking sight. A recent news report in these pages carried a picture of a sea turtle lying half ...
Budget presser
Updated 14 Jun, 2026

Budget presser

If the FBR falters, the government will find itself in hot water sooner rather than later.
Muharram precautions
14 Jun, 2026

Muharram precautions

WITH Muharram due to start next week, the authorities have already begun annual exercises to ensure that the ...
Blood bequests
14 Jun, 2026

Blood bequests

WORLD Blood Donor Day offers a moment of “gratitude, advocacy and renewed commitment” for thalassaemia patients...